PRTN3 and rheumatoid arthritis: Results from our analysis indicate that, despite suppression of inflammation and adoption of prophylactic measures, ACPA-positive early RA patients are exposed to increased risk of systemic bone loss, especially at the spine, in the first two years after treatment start.